Grand Pharmaceutical Group Limited is an investment holding company operating in the pharmaceutical and biotechnology sectors. The company focuses on nuclear medicine for oncology and cardiovascular interventions, pharmaceutical technology, and biotechnology. Its business segments include radiopharmaceuticals, high-end formulations, and health and nutrition products, with a specific emphasis on amino acids. Key products and brands include the Y-90 resin microspheres, the Lai Te Ling (Olopatadine Mometasone) nasal spray, and the TP-03 treatment for Demodex blepharitis. The company maintains a partnership with Telix for radiopharmaceutical development, specifically for RDC products such as TLX101 and TLX591-CDx. It serves markets in China and is pursuing international expansion into North America and the European Union. The company's history dates back to 1939.

Summarised from the company's own disclosures, fiscal year ended Apr 2026

Industry Drug Manufacturers - General Homepage grandpharm.com
Sector Healthcare IR page grandpharm.com
Tags
nuclear medicine, radiopharmaceuticals, oncology, cardiovascular interventions, amino acids, health and nutrition, pharmaceutical technology, biotechnology, Telix, TLX101, TLX591-CDx, TLX250-CDx, Lai Te Ling, TP-03, Y-90 resin microspheres, Chengdu Pu'er Weiye Medical Technology Co. Ltd., Hebei Grand Jiufu
Press page grandpharm.com/news

Metrics

Valuation  
Market cap HK$ 14.78B
Market cap (USD) $ 1.884B
P/E 11.75
PEG —
P/BV 0.84
P/S 1.18
P/OCF 8.62
P/FCF —
Dividend yield 4.1%
Turnover / mcap 0.05%
Returns  
ROE 7.4%
ROI 6.2%
ROIC 6.2%
Profit margin 10.1%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) -15.8%
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity 28.8%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score 41.2%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010
Revenue 12.283B 11.645B 10.53B 9.562B 8.598B 6.353B 6.591B 5.958B 4.771B 3.696B 3.246B 3.122B 2.658B 2.059B 1.648B 1.055B
Net profit 1.241B 2.468B 1.88B 2.079B 2.403B 1.793B 1.151B 712.667M 460.811M 269.143M 180.906M 175.208M 99.658M 67.305M 54.235M 97.973M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010
Share price 0.27 5.99 3.81 4.29 7.79 6.88 4.6 5.2 — — — — — — — —
Price performance 12m -0.96 0.57 -0.11 -0.45 0.13 0.5 -0.12 — — — — — — — — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

Grand Pharmaceutical Group Limited (ticker 512), listed in Hong Kong.

ETFs Holding Grand Pharmaceutical Group Limited

ETF Weight in ETF Shares Market value As of
AVEE 0.06% 141,500 $ 77.989K Nov 16, 2026
AVES 0.02% 614,000 $ 338.41K Nov 16, 2026
AVSE 0.02% 70,000 $ 38.581K Nov 16, 2026
DFEV 0.02% 747,500 $ 413.073K Nov 12, 2026
AVEM 0.01% 6,919,500 $ 3.814M Nov 16, 2026
DFEM 0.01% 1,526,000 $ 843.277K Nov 12, 2026
DFAE 0.01% 1,308,000 $ 722.809K Nov 12, 2026
DFAX 0.00% 813,500 $ 449.545K Nov 12, 2026